Limits...
ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY - Cancer Sci. (2014)

Bottom Line: Multivariate analyses demonstrated that good PS, invasive ductal carcinoma, non-triple negative phenotype and initial operable stage were significantly associated with a lower death risk.Our results also suggest that the prediction of docetaxel toxicity might be possible for C3435T polymorphism.This study results provides valuable information on individualized therapy according to genotypes.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

Show MeSH

Related in: MedlinePlus

Overall survival (OS) according to ABCB1 C3435T polymorphism. ABCB1 C3435T TT genotype had longer OS compared to the others (P = 0.024).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317776&req=5

fig01: Overall survival (OS) according to ABCB1 C3435T polymorphism. ABCB1 C3435T TT genotype had longer OS compared to the others (P = 0.024).

Mentions: The overall clinical response rate (RR) was 76.8%. Twenty patients (9.3%) achieved clinical complete response (cCR) and 18 (8.3%) achieved pCR. Among the PK group, RR was 82.0% with 4.2% of pCR. ABCB1 C3435T, G2677T/A, and C1236T SNPs did not predict the responders. As shown in Figure1, ABCB1 3435TT genotype had a longer OS than the CT/TT genotype with statistical significance (P = 0.024). A similar trend was observed for the RFS, that is, ABCB1 3435TT genotype tended to have a longer RFS although it was not statistically significant (P = 0.234). ABCB1 G2677T/A and C1236T were analyzed, and there were no significant differences in the RFS and OS (Fig. S1).


ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.

Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY - Cancer Sci. (2014)

Overall survival (OS) according to ABCB1 C3435T polymorphism. ABCB1 C3435T TT genotype had longer OS compared to the others (P = 0.024).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317776&req=5

fig01: Overall survival (OS) according to ABCB1 C3435T polymorphism. ABCB1 C3435T TT genotype had longer OS compared to the others (P = 0.024).
Mentions: The overall clinical response rate (RR) was 76.8%. Twenty patients (9.3%) achieved clinical complete response (cCR) and 18 (8.3%) achieved pCR. Among the PK group, RR was 82.0% with 4.2% of pCR. ABCB1 C3435T, G2677T/A, and C1236T SNPs did not predict the responders. As shown in Figure1, ABCB1 3435TT genotype had a longer OS than the CT/TT genotype with statistical significance (P = 0.024). A similar trend was observed for the RFS, that is, ABCB1 3435TT genotype tended to have a longer RFS although it was not statistically significant (P = 0.234). ABCB1 G2677T/A and C1236T were analyzed, and there were no significant differences in the RFS and OS (Fig. S1).

Bottom Line: Multivariate analyses demonstrated that good PS, invasive ductal carcinoma, non-triple negative phenotype and initial operable stage were significantly associated with a lower death risk.Our results also suggest that the prediction of docetaxel toxicity might be possible for C3435T polymorphism.This study results provides valuable information on individualized therapy according to genotypes.

View Article: PubMed Central - PubMed

Affiliation: Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.

Show MeSH
Related in: MedlinePlus